Tweet
Wall Street brokerages forecast that Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) will announce earnings per share (EPS) of ($1.79) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Biohaven Pharmaceutical's earnings, with the lowest EPS estimate coming in at ($2.48) and the highest estimate coming in at ($1.09). Biohaven Pharmaceutical reported earnings of ($1.19) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 50.4%. The business is scheduled to report its next quarterly earnings results on Tuesday, November 13th.
On average, analysts expect that Biohaven Pharmaceutical will report full-year earnings of ($6.72) per share for the current fiscal year, with EPS estimates ranging from ($9.48) to ($5.04). For the next fiscal year, analysts anticipate that the business will post earnings of ($5.93) per share, with EPS estimates ranging from ($8.97) to ($4.15). Zacks Investment Research's earnings per share averages are an average based on a survey of analysts that that provide coverage for Biohaven Pharmaceutical. Get Biohaven Pharmaceutical alerts:
Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, May 15th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.12) by ($1.20). Several equities research analysts have recently commented on the company. Barclays upped their price objective on Biohaven Pharmaceutical to $40.00 and gave the stock an "equal weight" rating in a research note on Tuesday, June 19th. Morgan Stanley upped their price objective on Biohaven Pharmaceutical from $39.00 to $44.00 and gave the stock an "overweight" rating in a research note on Friday, July 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Biohaven Pharmaceutical in a research note on Thursday, June 14th. Canaccord Genuity set a $40.00 price objective on Biohaven Pharmaceutical and gave the stock a "buy" rating in a research note on Sunday, July 1st. Finally, Needham & Company LLC upped their price objective on Biohaven Pharmaceutical from $36.00 to $48.00 and gave the stock a "buy" rating in a research note on Monday, July 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of "Buy" and an average target price of $43.29.
In other Biohaven Pharmaceutical news, CFO James Engelhart sold 5,000 shares of the stock in a transaction on Wednesday, May 30th. The stock was sold at an average price of $35.00, for a total value of $175,000.00. Following the completion of the sale, the chief financial officer now owns 5,000 shares in the company, valued at approximately $175,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link . Also, Director Declan Doogan sold 110,784 shares of the stock in a transaction on Friday, June 1st. The stock was sold at an average price of $35.03, for a total value of $3,880,763.52. Following the completion of the sale, the director now owns 463,913 shares of the company's stock, valued at approximately $16,250,872.39. The disclosure for this sale can be found here . Insiders sold a total of 406,245 shares of company stock valued at $14,479,071 over the last 90 days. 34.20% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of BHVN. Geode Capital Management LLC increased its stake in Biohaven Pharmaceutical by 13.8% in the 4th quarter. Geode Capital Management LLC now owns 172,108 shares of the company's stock worth $4,643,000 after buying an additional 20,908 shares in the last quarter. Deutsche Bank AG increased its stake in Biohaven Pharmaceutical by 28.6% in the 4th quarter. Deutsche Bank AG now owns 23,580 shares of the company's stock worth $635,000 after buying an additional 5,248 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Biohaven Pharmaceutical in the 4th quarter worth $802,000. Wells Fargo & Company MN increased its stake in Biohaven Pharmaceutical by 38.2% in the 1st quarter. Wells Fargo & Company MN now owns 41,184 shares of the company's stock worth $1,060,000 after buying an additional 11,373 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Biohaven Pharmaceutical by 218.4% in the 1st quarter. Rhumbline Advisers now owns 27,933 shares of the company's stock worth $720,000 after buying an additional 19,160 shares in the last quarter. Institutional investors and hedge funds own 77.44% of the company's stock.
NYSE:BHVN opened at $35.10 on Tuesday. The firm has a market capitalization of $1.31 billion, a PE ratio of -7.02 and a beta of 1.35. Biohaven Pharmaceutical has a one year low of $16.50 and a one year high of $44.28.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter 